Repligen Corporation (RGEN)
Nasdaq: RGEN · Biological Products, (No Diagnostic Substances) · Waltham, MA · filing with the SEC since 1995
Grade5.4
◀ Past 6.3● Present 6.4▶ Future 4.1
Who owns Repligen Corporation
As filed with the SECHolders of 5% or more
3
Fmr LLC holds 13% of COMMON STOCK, as its SCHEDULE 13G/A filed Oct 7, 2026 says.
Directors and officers
15
report now, of 22 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Fmr LLC
SCHEDULE 13G/A · filed Oct 7, 2026 · COMMON STOCK · 5.1% in Feb 5, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Apr 24, 2025 · Common Stock
Vanguard Capital Management
SCHEDULE 13G · filed Jul 31, 2026 · Common Stock
Roy T. Eddleman Living Trust
SCHEDULE 13G/A · filed Feb 13, 2025 · Common Stock, $.01 par value per share · reported falling below 5%
Roy T. Eddleman Living Trust
SCHEDULE 13G/A · filed Feb 13, 2026 · Common Stock, $.01 par value per share · reported falling below 5%
T. Rowe Price Associates, Inc.
SCHEDULE 13G/A · filed Aug 14, 2026 · COMMON STOCK · reported falling below 5%, from 8.2% in Feb 17, 2026
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%
What RGEN reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
FlexBiosys, Inc.
A company bought · acquisition · Dec 2023 · owns, named in the 10-K filed Feb 26, 2026
Metenova Holding AB
A company bought · acquisition · Dec 2023 · owns, named in the 10-K filed Feb 26, 2026
908 Devices Inc. Bioprocessing Analytics Portfolio
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
Avitide LLC
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
Tantti Laboratory Inc
A company bought · acquisition · owns, named in the 10-K filed Feb 26, 2026
17 subsidiaries in 14 countries, from the list filed with the 10-K filed Feb 26, 2026.
Insider tradesForm 4
25sales
0purchases
16sales on a scheduled plan
5people selling
$15.3Msold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Oct 8, 2025 to Oct 8, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Oct 8, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window5 of 23 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Loeillot Olivier | Chief Executive Officer | 9 | $7.7M | 9 | 0 | $0 |
| Hunt Anthony | Chief Executive Officer | 12 | $7.0M | 5 | 0 | $0 |
| Bylund James | Chief Operating Officer | 1 | $300,000 | 0 | 0 | $0 |
| Garland Jason K | CFO | 2 | $200,000 | 2 | 0 | $0 |
| Dawes Karen A | director | 1 | $0 | 0 | 0 | $0 |